DLC-1:a Rho GTPase-activating protein and tumour suppressor: Special Review Article

Journal of Cellular and Molecular Medicine

Volumn 11, Issue 5, 2007, Pages 1185-1207

  Durkin, Marian E ^a   Yuan, Bao Zhu ^b   Zhou, Xiaoling ^a   Zimonjic, Drazen B ^a   Lowy, Douglas R ^a   Thorgeirsson, Snorri S ^a   Popescu, Nicholas C ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^c MSC 4262 ^*  (United States)

Author keywords

Cancer detection; Cancer therapy; Cytoskeletal organization; Deleted in liver cancer; Focal adhesion; GTPase activating protein; Metastasis suppressor; Tensin; Tumour suppressor

Indexed keywords

GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; RHO GTPASE ACTIVATING PROTEIN; RHO GTPASE-ACTIVATING PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CHEMISTRY; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; NEOPLASM; PATHOLOGY; PROTEIN TERTIARY STRUCTURE;

AMINO ACID SEQUENCE; ANIMALS; GTPASE-ACTIVATING PROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA; INVERTEBRATA;

EID: 35648981592     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2007.00098.x     Document Type: Article

References (132)

1. Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997 11 : 2295 322.
2. Ridley AJ. Rho family proteins: coordinating cell responses. Trends Cell Biol. 2001 11 : 471 7.
3. Jaffe AB, Hall A. Rho-GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005 21 : 247 69.
4. Sahai E, Marshall CJ. Rho-GTPases and cancer. Nat Rev Cancer. 2002 2 : 133 42.
5. Gomez del Pulgar T, Benitah SA, Valeron PF, Espina C, Lacal JC. Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays. 2005 27 : 602 13.
6. Wennerberg K, Der CJ. Rho-family GTPases:it's not only Rac and Rho (and I like it). J Cell Sci. 2004 117 : 1301 12.
7. Boureux A, Vignal E, Faure S, Fort P. Evolution of the Rho family of Ras-like GTPases in eukaryotes. Mol Biol Evol. 2007 24 : 203 16.
8. Bos JL, Rehmann H, Wittinghofer A. GEFs and GAPs:critical elements in the control of small G proteins. Cell. 2007 129 : 865 77.
9. Rossman KL, Der CJ, Sondek J. GEF means go: turning on Rho GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol. 2005 6 : 167 80.
10. Moon SY, Zheng Y. Rho GTPase-activating proteins in cell regulation. Trends Cell Biol. 2003 13 : 13 22.
11. Bernards A. GAPs galore A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim Biophys Acta. 2003 1603 : 47 82.
12. Tcherkezian J, Lamarche-Vane N. Current knowledge of the large RhoGAP family of proteins. Biol Cell. 2007 99 : 67 86.
13. Marinissen MJ, Gutkind JS. Scaffold proteins dictate Rho GTPase-signaling specificity. Trends Biochem Sci. 2005 30 : 423 6.
14. García-Mata R, Burridge K. Catching a GEF by its tail. Trends Cell Biol. 2007 17 : 36 43.
15. Wang L, Zheng Y. Cell type-specific functions of Rho GTPases revealed by gene targeting in mice. Trends Cell Biol. 2007 17 : 58 64.
16. Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res. 1998 58 : 2196 9.
17. Homma Y, Emori Y. A dual functional signal mediator showing RhoGAP and phosopholipase C- stimulating activities. EMBO J. 1995 14 : 286 91.
18. Ponting CP, Aravind L. START: a lipid-binding domain in StAR, HD-ZIP and signalling proteins. Trends Biochem Sci. 1999 24 : 130 2.
19. Ching YP, Wong CM, Chan SF, Leung TH, Ng DC, Jin DY, Ng IO. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem. 2003 278 : 10824 30.
20. Nagaraja GM, Kandpal RP. Chromosome 13q12 encoded Rho GTPase activating protein suppresses growth of breast carcinoma cells, and yeast two-hybrid screen shows its interaction with several proteins. Biochem Biophys Res Commun. 2004 313 : 654 65.
21. Nagase T, Seki N, Ishikawa K, Tanaka A, Nomura N. Prediction of the coding sequences of unidentified human genes. V. The coding sequences of 40 new genes (KIAA0161-KIAA0200) deduced by analysis of cDNA clones from human cell line KG-1. DNA Res. 1996 3 : 17 24.
22. Durkin ME, Ullmannova V, Guan M, Popescu NC. Deleted in Liver Cancer 3 (DLC-3), a novel Rho GTPase activating protein, is downregulated in cancer and inhibits tumor cell growth. Oncogene. 2007 26 : 4580 9.
23. Schimdt A, Schmelzle T, Hall MN. The RHO1-GAPs SAC7, BEM2 and BAG7 control distinct RHO1 functions in Saccharomyces cerevisiae. Mol Microbiol. 2002 45 : 1433 41.
24. Durkin ME, Yuan BZ, Thorgeirsson SS, Popescu NC. Gene structure, tissue expression, and linkage mapping of the mouse DLC-1 gene (Arhgap7). Gene. 2002 288 : 119 27.
25. Yuan BZ, Yang Y, Keck-Waggoner CL, Zimonjic DB, Thorgeirsson SS, Popescu NC. Assignment and cloning of mouse Arhgap7 to chromosome 8A4-B2, a conserved syntenic region of human chromosome 8p22®p21. Cytogenet Cell Genet. 1999 87 : 189 90.
26. Nagase T, Kikuno R, Hattori A, Kondo Y, Okumura K, Ohara O. Prediction of the coding sequences of unidentified human genes. XIX. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res. 2000 7 : 347 55.
27. Leung TH, Ching YP, Yam JW, Wong CM, Yau TO, Jin DY, Ng IO. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci USA. 2005 102 : 15207 12.
28. Denholm B, Brown S, Ray RP, Ruiz-Gomez M, Skaer H, Hombria JC. Crossveinless-c is a RhoGAP required for actin reorganisation during morphogene-sis. Development. 2005 132 : 2389 400.
29. Tsuboi D, Qadota H, Kasuya K, Amano M, Kaibuchi K. Isolation of the interacting molecules with GEX-3 by a novel functional screening. Biochem Biophys Res Commun. 2002 292 : 697 701.
30. Wilson PJ, McGlinn E, Marsh A, Evans T, Arnold J, Wright K, Biden K, Young J, Wainwright B, Wicking C, Chenevix-Trench G. Sequence variants of DLC1 in colorectal and ovarian tumours. Hum Mutat. 2000 15 : 156 65.
31. Durkin ME, Avner MR, Huh CG, Yuan BZ, Thorgeirsson SS, Popescu NC. DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. FEBS Lett. 2005 579 : 1191 6.
32. Yuan BZ, Durkin ME, Popescu NC. Promoter hyper-methylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. Cancer Genet Cytogenet. 2003 140 : 113 7.
33. Kim TY, Jong HS, Song SH, Dimtchev A, Jeong SJ, Lee JW, Kim TY, Kim NK, Jung M, Bang YJ. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene. 2003 22 : 3943 51.
34. Seng TJ, Low JS, Li H, Cui Y, Goh HK, Wong ML, Srivastava G, Sidransky D, Califano J, Steenbergen RD, Rha SY, Tan J, Hsieh WS, Ambinder RF, Lin X, Chan AT, Tao Q. The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene. 2007 26 : 934 44.
35. Qiao F, Bowie JU. The many faces of SAM. Sci STKE. 2005 2005 : re7.
36. Li H, Fung KL, Jin DY, Chung SS, Ching YP, Ng IO, Sze KH, Ko BC, Sun H. Solution structures, dynamics, and lipid-binding of the sterile alpha-motif domain of the deleted in liver cancer 2. Proteins. 2007 67 : 1154 66.
37. Kwan JJ, Donaldson LW. The NMR structure of the murine DLC2 SAM domain reveals a variant fold that is similar to a four-helix bundle. BMC Struct Biol. 2007 7 : 34.
38. Li G, Zhang XC. GTP hydrolysis mechanism of Ras-like GTPases. J Mol Biol. 2004, 340 : 921 32.
39. Sekimata M, Kabuyama Y, Emori Y, Homma Y. Morphological changes and detachment of adherent cells induced by p122, a GTPase-activating protein for Rho. J Biol Chem. 1999 274 : 17757 62.
40. Wong CM, Lee JM, Ching YP, Jin DY, Ng IO. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res. 2003 63 : 7646 51.
41. Qian X, Li G, Asmussen HK, Asnaghi L, Vass WC, Braverman R, Yamada KM, Popescu NC, Papageorge AG, Lowy DR. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci USA. 2007 104 : 9012 7.
42. Alpy F, Tomasetto C. Give lipids a START: the StAR-related lipid transfer (START) domain in mammals. J Cell Sci. 2005 118 : 2791 801.
43. Bernards A, Settleman J. GAP control: regulating the regulators of small GTPases. Trends Cell Biol. 2004 14 : 377 85.
44. Tsujishita Y, Hurley JH. Structure and lipid transport mechanism of a StAR-related domain. Nat Struct Biol. 2000 7 : 408 14.
45. Brown MC, Curtis MS, Turner CE. Paxillin LD motifs may define a new family of protein recognition domains. Nat Struct Biol. 1998 5 : 677 8.
46. Li SS. Specificity and versatility of SH3 and other proline-recognition domains: structural basis and implications for cellular signal transduction. Biochem J. 2005 390 : 641 53.
47. Tompa P. Intrinsically unstructured proteins. Trends Biochem Sci. 2002 27 : 527 33.
48. Radivojac P, Iakoucheva LM, Oldfield CJ, Obradovic Z, Uversky VN, Dunker AK. Intrinsic disorder and functional proteomics. Biophys J. 2007 92 : 1439 56.
49. Hers I, Wherlock M, Homma Y, Yagisawa H, Tavaré JM. Identification of p122RhoGAP (deleted in liver cancer-1) Serine 322 as a substrate for protein kinase B and ribosomal S6 kinase in insulin-stimulated cells. J Biol Chem. 2006 281 : 4762 70.
50. Hoffert JD, Pisitkun T, Wang G, Shen RF, Knepper MA. Quantitative phosphoproteomics of vasopressin-sensitive renal cells:regulation of aquaporin-2 phos-phorylation at two sites. Proc Natl Acad Sci USA. 2006 103 : 7159 64.
51. Villén J, Beausoleil SA, Gerber SA, Gygi SP. Large-scale phosphorylation analysis of mouse liver. Proc Nat Acad Sci USA. 2007 104 : 1488 93.
52. Songyang Z, Blechner S, Hoagland N, Hoekstra MF, Piwnica-Worms H, Cantley LC. Use of an oriented peptide library to determine the optimal substrates of protein kinases. Curr Biol. 1994 4 : 973 82.
53. Brunton VG, MacPherson IRJ, Frame MC. Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry. Biochim Biophys Acta. 2004 1692 : 121 44.
54. Burridge K, Wennerberg K. Rho and Rac take center stage. Cell. 2004 116 : 167 79.
55. Wong CM, Yam JW, Ching YP, Yau TO, Leung TH, Jin DY, Ng IO. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res. 2005 65 : 8861 8.
56. Kim TY, Lee JW, Kim HP, Jong HS, Kim TY, Jung M, Bang YJ. DLC-1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology and migration in human hepatocellular carcinoma. Biochem Biophys Res Commun. 2007 355 : 72 7.
57. Zhou X, Thorgeirsson SS, Popescu NC. Restoration of DLC-1 gene expression induces apop-tosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene. 2004 23 : 1308 13.
58. Kawai K, Yamaga M, Iwamae Y, Kiyota M, Kamata H, Hirata H, Homma Y, Yagisawa H. A PLCδ 1-binding protein, p122RhoGAP, is localized in focal adhesions. Biochem Soc Trans. 2004 32 : 1107 9.
59. Yam JW, Ko FC, Chan CY, Jin DY, Ng IO. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res. 2006 66 : 8367 72.
60. Liao YC, Si L, deVere White RW, Lo SH. The phos-photyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J Cell Biol. 2007 176 : 43 9.
61. Lo SH. Tensin. Int J Biochem Cell Biol. 2004 36 : 31 4.
62. Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev. 2004 84 : 1341 79.
63. Yamaga M, Sekimata M, Fujii M, Kawai K, Kamata H, Hirata H, Homma Y, Yagisawa H. A PLC 1-binding protein, p122/RhoGAP, is localized in caveolin-enriched membrane domains and regulates caveolin internalization. Genes Cells. 2004 9 : 25 37.
64. Parton RG, Simons K. The multiple faces of caveo-lae. Nat Rev Mol Cell Biol. 2007 8 : 185 94.
65. Swaney JS, Patel HH, Yokoyama U, Head BP, Roth DM, Insel PA. Focal adhesions in (myo)fibroblasts scaffold adenylyl cyclase with phosphorylated cave-olin. J Biol Chem. 2006 281 : 17173 9.
66. Rhee SG. Regulation of phosphoinositide-specific phospholipase C. Annu Rev Biochem. 2001, 70 : 281 312.
67. Niggli V. Regulation of protein activities by phospho-inositide phosphates. Annu Rev Cell Dev Biol. 2005 21 : 57 79.
68. Ng DC, Chan SF, Kok KH, Yam JW, Ching YP, Ng IO, Jin DY. Mitochondrial targeting of growth suppressor protein DLC2 through the START domain. FEBS Lett. 2006 580 : 191 8.
69. Ferrell JE Jr. What do scaffold proteins really do? Sci STKE. 2000 2000 : PE1.
70. Billuart P, Winter GG, Maresh A, Zhao X, Luo L. Regulating axon branch stability: the role of p190 RhoGAP in repressing a retraction signaling pathway. Cell. 2001 107 : 195 207.
71. Brodu V, Casanova J. 2006. The RhoGAP crossvein-less-c links trachealess and EGFR signaling to cell shape remodeling in Drosophila tracheal invagina-tion. Genes Dev. 2006 20 : 1817 28.
72. Simões S, Denholm B, Azevedo D, Sotillos S, Martin P, Skaer H, Hombria JC, Jacinto A. Compartmentalisation of Rho regulators directs cell invagination during tissue morphogenesis. Development. 2006 133 : 4257 67.
73. Soto MC, Qadota H, Kasuya K, Inoue M, Tsuboi D, Mello CC, Kaibuchi K. The GEX-2 and GEX-3 proteins are required for tissue morphogenesis and cell migrations in C. elegans. Genes Dev. 2002 16 : 620 32.
74. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 100 : 57 70
75. Jaffe AB, Hall A. Rho GTPases in transformation and metastasis. Adv Cancer Res. 2002 84 : 57 80.
76. Ng IO, Liang ZD, Cao L, Lee TK. DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1. Cancer Res. 2000 60 : 6581 4.
77. Plaumann M, Seitz S, Frege R, Estevez-Schwarz L, Scherneck S. Analysis of DLC-1 expression in human breast cancer. J Cancer Res Clin Oncol. 2003 129 : 349 54.
78. Gatalica Z, Velagaleti G, Kuivaniemi H, Tromp G, Palazzo J, Graves KM, Guigneaux M, Wood T, Sinha M, Luxon B. Gene expression profile of an adenomyoepithelioma of the breast with a reciprocal translocation involving chromosomes 8 and 16. Cancer Genet Cytogenet. 2005 156 : 14 22.
79. Ullmannova V, Popescu NC. Expression profile of the tumor suppressor genes DLC-1 and DLC-2 in solid tumors. Int J Oncol. 2006 29 : 1127 32.
80. Zhang X, Feng J, Cheng Y, Yao Y, Ye X, Fu T, Cheng H. Characterization of differentially expressed genes in ovarian cancer by cDNA microarrays. Int J Gynecol Cancer. 2005, 15 : 50 7.
81. Yuan BZ, Jefferson AM, Baldwin TK, Thorgeirsson SS, Popescu NC, Reynolds SH. DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene. 2004 23 : 1405 11.
82. Dammann R, Strunnikova M, Schagdarsurengin U, Rastetter M, Papritz M, Hattenhorst UE, Hofmann HS, Silber RE, Burdach S, Hansen G. CpG island methylation and expression of tumour-associated genes in lung carcinoma. Eur J Cancer. 2005 41 : 1223 36.
83. Healy KD, Kim TY, Shutes AT, Bang YJ, Juliano RL, Der CJ. RhoGAP DLC-1 tumor suppression and aberrant Rho GTPase activation in lung cancer. Proc Am Assoc Cancer Res. 2006 47 : 970.
84. Nakamura T, Furukawa Y, Nakagawa H, Tsunoda T, Ohigashi H, Murata K, Ishikawa O, Ohgaki K, Kashimura N, Miyamoto M, Hirano S, Kondo S, Katoh H, Nakamura Y, Katagiri T. Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene. 2004 23 : 2385 400.
85. Guan M, Zhou X, Soulitzis N, Spandidos DA, Popescu NC. Aberrant methylation and deacetyla-tion of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res. 2006 12 : 1412 9.
86. Peng D, Ren CP, Yi HM, Zhou L, Yang XY, Li H, Yao KT. Genetic and epigenetic alterations of DLC-1, a candidate tumor suppressor gene, in nasopharyngeal carcinoma. Acta Biochim Biophys Sin. 2006 38 : 349 55.
87. Hoffman PJ, Milliken DB, Gregg LC, Davis RR, Gregg JP. Molecular characterization of uterine fibroids and its implication for underlying mechanisms of pathogenesis. Fertil Steril. 2004 82 : 639 49.
88. Struski S, Doco- Fenzy M, Cornillet-Lefebvre P. Compilation of published comparative genomic hybridization studies. Cancer Genet Cytogenet. 2002 135 : 63 90.
89. Yuan BZ, Zhou X, Durkin ME, Zimonjic DB, Gumundsdottir K, Eyfjord JE, Thorgeirsson SS, Popescu NC. DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene. 2003, 22 : 445 50.
90. Popescu NC. Genetic alterations in cancer as a result of breakage at fragile sites. Cancer Lett. 2003 92 : 1 17.
91. Popescu NC. Fragile sites and cancer genes on the short arm of chromosome 8. Lancet Oncol. 2004 5 : 77.
92. Kost-Alimova M, Imreh S. Modeling non-random deletions in cancer. Semin Cancer Biol. 2007 17 : 19 30.
93. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Eng J Med. 2003 349 : 2042 54.
94. Teramoto A, Tsukuda K, Yano M, Toyooka S, Dote H, Doihara H, Shimizu N. Less frequent promoter hypermethylation of DLC-1 gene in primary breast cancers. Oncol Rep. 2004 12 : 141 4.
95. Zhang Q, Ying J, Zhang K, Li H, Ng KM, Zhao Y, He Q, Yang X, Xin D, Liao SK, Tao Q, Jin J. Aberrant methylation of the 8p22 tumor suppressor gene DLC1 in renal cell carcinoma. Cancer Lett. 2007 249 : 220 6.
96. Song YF, Xu R, Zhang XH, Chen BB, Chen Q, Chen YM, Xie Y. High-frequency promoter hypermethyla-tion of the deleted in liver cancer-1 gene in multiple myeloma. J Clin Pathol. 2006 59 : 947 51.
97. Shi H, Guo J, Duff DJ, Rahmatpanah F, Chitima-Matsiga R, Al-Kuhlani M, Taylor KH, Sjahputera O, Andreski M, Wooldridge JE, Caldwell CW. Discovery of novel epigenetic markers in non-Hodgkin's lymphoma. Carcinogenesis. 2007 28 : 60 70.
98. Taylor KH, Pena-Hernandez KE, Davis JW, Arthur GL, Duff DJ, Shi H, Rahmatpanah FB, Sjahputera O, Caldwell CW. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res. 2007 67 : 2617 25.
99. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer:caus-es and therapies. Nat Rev Cancer. 2001 1 : 194 202.
100. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek MA, Zhao M, Smith BD, Manning J, Jiemjit A, Dover G, Mays A, Zwiebel J, Murgo A, Weng LJ, Herman JG. Combined DNA methyltrans-ferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Re. 2006 66 : 6361 9.
101. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006 6 : 846 56.
102. Bracken A, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 2006 20 : 1123 36.
103. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, Chevalier B, Johnstone SE, Cole MF, Isono K, Koseki H, Fuchikami T, Abe K, Murray HL, Zucker JP, Yuan B, Bell GW, Herbolsheimer E, Hannett NM, Sun K, Odom DT, Otte AP, Volkert TL, Bartel DP, Melton DA, Gifford DK, Jaenisch R, Young RA. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell. 2006 125 : 301 13.
104. Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I, Laird PW. Epigenetic stem cell signature in cancer. Nat Genet. 2007 39 : 157 8.
105. Park SW, Durkin ME, Thorgeirsson SS, Popescu NC. DNA variants of DLC-1, a candidate tumor suppressor gene in human hepatocellular carcinoma. Int J Oncol. 2003 23 : 133 7.
106. Pang JC, Chang Q, Chung YF, Teo JG, Poon WS, Zhou LF, Kong X, Ng HK. Epigenetic inactivation of DLC-1 in supratentorial primitive neuroectodermal tumor. Hum Pathol. 2005 36 : 36 43.
107. Hewitt C, Wilson P, McGlinn E, MacFarlane G, Papageorgiou A, Woodwards RT, Sloan P, Gollin SM, Paterson I, Parkinson KK, Read AP, Thakker N. DLC1 is unlikely to be a primary target for deletions on chromosome arm 8p22 in head and neck squamous cell carcinoma. Cancer Lett. 2004 209 : 207 13.
108. Zheng SL, Mychaleckyj JC, Hawkins GA, Isaacs SD, Wiley KE, Turner A, Chang BL, von Kap-Herr C, Carpten JD, Pettenati M, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB, Xu J. Evaluation of DLC1 as a prostate cancer susceptibility gene: mutation screen and association study. Mutat Res. 2003 528 : 45 53.
109. Chang BL, Liu W, Sun J, Dimitrov L, Li T, Turner AR, Zheng SL, Isaacs WB, Xu J. Integration of somatic deletion analysis of prostate cancers and germline linkage analysis of prostate cancer families reveals two small consensus regions for prostate cancer genes at 8p. Cancer Res. 2007 67 : 4098 103.
110. Tang K, Oeth P, Kammerer S, Denissenko MF, Ekblom J, Jurinke C, van den Boom D, Braun A, Cantor CR. Mining disease susceptibility genes through SNP analyses and expression profiling using MALDI-TOF mass spectrometry. J Proteome Res. 2004 3 : 218 27.
111. van den Boom D, Beaulieu M, Oeth P, Roth R, Honisch C, Nelson MR, Jurinke C, Cantor C. MALDI-TOF MS: a platform technology for genetic discovery. Int J Mass Spectrom. 2004 238 : 173 88.
112. Syed V, Mukherjee K, Lyons-Weiler J, Lau KM, Mashima T, Tsuruo T, Ho SM. Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumori-genic, progesterone-regulated genes for ovarian cancer cells by gene profiling. Oncogene. 2005 24 : 1774 87.
113. Qin LX. Chromosomal aberrations related to metastasis of human solid tumors. World J Gastroenterol. 2002 8 : 769 76.
114. Song LJ, Ye SL, Wang KF, Weng YQ, Liang CM, Sun RX, Zhao Y, Liu YK, Tang ZY. Relationship between DLC-1 expressions and metastasis in hepa-tocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi. 2005 13 : 428 31.
115. Goodison S, Yuan J, Sloan D, Kim R, Li C, Popescu NC, Urquidi V. The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res. 2005 65 : 6042 53.
116. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise TA, Massagué J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003 3 : 537 49.
117. Folgueira MA, Carraro DM, Brentani H, Patrão DF, Barbosa EM, Netto MM, Caldeira JR, Katayama ML, Soares FA, Oliveira CT, Reis LF, Kaiano JH, Camargo LP, Vêncio RZ, Snitcovsky IM, Makdissi FB, e Silva PJ, Góes JC, Brentani MM. Gene expression profile associated with response to dox-orubicin-based therapy in breast cancer. Clin Cancer Res. 2005 11 : 7434 43.
118. Czernicki T, Zegarska J, Paczek L, Cukrowska B, Grajkowska W, Zajaczkowska A, Brudzewski K, Ulaczyk J, Marchel A. Gene expression profile as a prognostic factor in high-grade gliomas. Int J Oncol. 2007 30 : 55 64.
119. Mas VR, Fisher RA, Archer KJ, Yanek KC, Williams B, Dumur CI, Maluf DG. Genes associated with progression and recurrence of hepatocellular carcinoma in hepatitis C patients waiting and undergoing liver transplantation: preliminary results. Transplantation. 2007 83 : 973 81.
120. Basso K, Liso A, Tiacci E, Benedetti R, Pulsoni A, Foa R, Di Raimondo F, Ambrosetti A, Califano A, Klein U, Dalla Favera R, Falini B. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med. 2004 199 : 59 68.
121. Ross ME, Mahfouz R, Onciu M, Liu HC, Zhou X, Song G, Shurtleff SA, Pounds S, Cheng C, Ma J, Ribeiro RC, Rubnitz JE, Girtman K, Williams WK, Raimondi SC, Liang DC, Shih LY, Pui CH, Downing JR. Gene expression profiling of pediatric acute myel-ogenous leukaemia. Blood. 2004 104 : 3679 87.
122. Herzog A, Kindermann B, Döring F, Daniel H, Wenzel U. Pleiotropic molecular effects of the pro-apoptotic dietary constituent flavone in human colon cancer cells identified by protein and mRNA expression profiling. Proteomics. 2004 4 : 2455 64.
123. Ullmannova V, Popescu NC. Inhibition of cell proliferation, induction of apoptosis, reactivation of DLC1, and modulation of other gene expression by dietary flavone in breast cancer cell lines. Cancer Detect Prev. 2007 31 : 110 8.
124. Zirn B, Samans B, Spangenberg C, Graf N, Eilers M, Gessler M. All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene. 2005 24 : 5246 51.
125. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM. Retinoids in chemopreven-tion and differentiation therapy. Carcinogenesis. 2000 21 : 1271 9.
126. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 2004 5 : 419 29.
127. Bren-Mattison Y, Van Putten V, Chan D, Winn R, Geraci MW, Nemenoff RA. Peroxisome proliferator-activated receptor- (PPAR) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene. 2005 24 : 1412 22.
128. Asada K, Asada R, Yoshiji H, Fukui H, Floyd RA, Kotake Y. DNA cytosine methylation profile in various cancer-related genes is altered in cultured rat hepa-tocyte cell lines as compared with primary hepato-cytes. Oncol Rep. 2006 15 : 1241 8.
129. Ushijima T, Yamamoto M, Suzui M, Kuramoto T, Yoshida Y, Nomoto T, Tatematsu M, Sugimura T, Nagao M. Chromosomal mapping of genes controlling development, histological grade, depth of invasion, and size of rat stomach carcinomas. Cancer Res. 2000 60 : 1092 6.
130. Edelson MI, Lau CC, Colitti CV, Welch WR, Bell DA, Berkowitz RS, Mok SC. A one centimorgan deletion unit on chromosome Xq12 is commonly lost in borderline and invasive epithelial ovarian tumors. Oncogene. 1998 16 : 197 202.
131. Spatz A, Borg C, Feunteun J. X-chromosome genetics and human cancer. Nat Rev Cancer. 2004 4 : 617 29.
132. Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE. The consensus coding sequences of human breast and col-orectal cancers. Science. 2006 314 : 268 74.